On May 20, we recognize International Clinical Trials Day: a time to honor everyone who makes clinical research possible, especially the people living with rare diseases who choose to participate in clinical studies.
For the rare disease community, clinical trials are more than a scientific milestone. They can mean extra appointments, travel, tests, and uncertainty – on top of the everyday realities of living with a serious condition. Yet patients and caregivers still show up with determination and hope. That decision takes courage.
Every clinical trial participant in the rare disease community helps expand understanding, strengthen the evidence, and move the field closer to new, and potentially transformative, treatments for the entire community.
This year’s theme, “Research Rising,” is a fitting reminder that progress rises through partnership: patients who place their trust in research, families who hold onto possibility, and the clinical research professionals who conduct studies with care, integrity and rigor.
To everyone who has participated in a rare disease clinical trial or helped a loved one participate – including those in the phenylketonuria (PKU), Duchenne muscular dystrophy (DMD), aromatic l-amino acid decarboxylase (AADC) deficiency, Friedrich’s ataxia (FA), and Huntington’s disease (HD) communities, we want to say thank you. You are helping to shape what we learn and what may be possible for future generations.
At PTC, we mark Clinical Trials Day with gratitude and commitment, continuing to listen, learn and work with urgency and respect alongside the rare disease community.